Have a personal or library account? Click to login
Which patient is going to benefit from surgical cytoreduction with intraperitoneal chemotherapy (for manifest peritoneal metastases)? Cover

Which patient is going to benefit from surgical cytoreduction with intraperitoneal chemotherapy (for manifest peritoneal metastases)?

Current Issues in Pharmacy and Medical Sciences
Volume 30 (2017): Issue 4 (December 2017)
By: Sebastian Blaj and  Pompiliu Piso  
Open Access
|Mar 2018

Authors

Sebastian Blaj

Klinik für Allgemein- und Viszeralchirurgie, Krankenhaus Barmherzige Brüder Regensburg, Regensburg, Germany

Pompiliu Piso

pompiliu.piso@barmherzige-regensburg.de

Klinik für Allgemein- und Viszeralchirurgie, Krankenhaus Barmherzige Brüder Regensburg, Regensburg, Germany
DOI: https://doi.org/10.1515/cipms-2017-0040 | Journal eISSN: 2300-6676 | Journal ISSN: 2084-980X
Journal RSS Feed
Language: English
Page range: 207 - 210
Submitted on: Dec 18, 2017
|
Accepted on: Dec 29, 2017
|
Published on: Mar 9, 2018
Published by: Sciendo
In partnership with: Paradigm Publishing Services
Publication frequency: 4 issues per year
Keywords:
peritoneal neoplasms,
hyperthermia,
induced,
stomach neoplasms,
cytoreduction surgical procedures,
induction chemotherapy,
laparoscopy
Related subjects:
Medicine,
Clinical medicine,
Clinical medicine, other,
Pharmacology, toxicology,
Pharmacy,
Pharmacy, other

© 2018 Sebastian Blaj, Pompiliu Piso, published by Sciendo
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.

Previous articleVolume 30 (2017): Issue 4 (December 2017)